A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.
NCT05834348 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5279
Last updated 2025-03-30
Summary
The main purpose of the study is to learn about the effectiveness and treatment sequence of lung cancer medicines. This study is performed outside of clinical trials in Norway in patients with metastatic non-small cell lung cancer. Non-small cell lung cancer is a group of lung cancers named for the kinds of cells found in the cancer and how the cells look under a microscope. Metastasis is when the cancer cells spread to other parts of the body.
This study includes patient's data from the database who:
* Are 18 years of age or older.
* Are confirmed to have metastatic non-small cell lung cancer between 01 January 2009 and 31 December 2022.
The study is based on data collection from 3 national health registries:
* The Cancer Registry of Norway (CRN),
* The Norwegian Patient Registry (NPR),
* The Norwegian Drug Registry (NDR).
Data from these registries will be linked at an individual patient level to create a single, unified dataset. The information collected includes:
Diagnosis, cancer stage at diagnosis, date of diagnosis, birth year, type of medicinal treatment, date of treatment start and end, treating hospital, age, gender, etc.
Conditions
Interventions
- DRUG
-
lorlatinib
As provided in real world practice
- DRUG
-
As provided in real world practice
- DRUG
-
As provided in real world practice
- DRUG
-
ceritinib
As provided in real world practice
- DRUG
-
alectinib
As provided in real world practice
- DRUG
-
As provided in real world practice
- DRUG
-
As provided in real world practice
- DRUG
-
As provided in real world practice
- DRUG
-
As provided in real world practice
- DRUG
-
As provided in real world practice
- DRUG
-
erlotinib
As provided in real world practice
- DRUG
-
gefitinib
As provided in real world practice
- DRUG
-
afatinib
As provided in real world practice
- DRUG
-
dacomitinib
As provided in real world practice
- DRUG
-
As provided in real world practice
- DRUG
-
As provided in real world practice
- DRUG
-
As provided in real world practice
- DRUG
-
entrectinib
As provided in real world practice
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Pfizer CT.gov Call Center · Pfizer
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-06-23
- Primary Completion
- 2024-01-23
- Completion
- 2024-01-23
Countries
- Norway
Study Locations
More Related Trials
-
MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy
NCT01294306 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Gemcitabine/Platinum +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
NCT00112346 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
NCT00532155 ·Status: COMPLETED ·Phase: PHASE3
-
Study of the Efficacy of an Investigational Drug in Adult Patients With Non Small-Cell Lung Cancer (NSCLC)
NCT00034957 ·Status: COMPLETED ·Phase: PHASE2
-
Anti-angiogenesis Agent AG-013736 in Patients With Advanced Non-Small Cell Lung Cancer
NCT00094094 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of All-trans Retinoic Acid With Chemotherapy Based in Paclitaxel and Cisplatin as First Line Treatment of Patients With Advanced Non-small Cell Lung Cancer
NCT01048645 ·Status: COMPLETED ·Phase: PHASE2
-
Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities
NCT05311709 ·Status: RECRUITING ·Phase: PHASE2
-
Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib
NCT05948462 ·Status: WITHDRAWN ·Phase: PHASE2
-
Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study
NCT04392505 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
NCT02664935 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer
NCT00994123 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT02574078 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
An Observational Study on Patients With Non-Squamous NSCLC Who Reached A Long PFS After Avastin (Bevacizumab)-Based First-Line Therapy
NCT01343914 ·Status: COMPLETED
-
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)
NCT05170204 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study
NCT03381274 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung Cancer
NCT00544960 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
NCT05384626 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of RO5083945 in Combination With Chemotherapy Versus Chemotherapy Alone in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
NCT01185847 ·Status: COMPLETED ·Phase: PHASE2
-
To Compare Efficacy and Safety of CT-P16 and European Union-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer
NCT03676192 ·Status: COMPLETED ·Phase: PHASE3
-
Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT01557959 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)
NCT02584634 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Olaparib Dose Escalating Trial + Concurrent RT With or Without Cisplatin in Locally Advanced NSCLC
NCT01562210 ·Status: COMPLETED ·Phase: PHASE1
-
A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients With Stage IIIB/IV Non-small Cell Lung Cancer Who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens
NCT00294736 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Naive to Chemotherapy
NCT02013206 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT02546986 ·Status: COMPLETED ·Phase: PHASE2